Bio-Rad Reports First-Quarter 2026 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Wells Fargo raises oil price targets citing ongoing supply risks
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
Bio-Rad Labs (BIO) Tops Q1 EPS by 5c, Beats on Revenue; Offers Guidance
April 30, 2026 4:24 PM EDTBio-Rad Labs (NYSE: BIO) reported Q1 EPS of $1.89, $0.05 better than the analyst estimate of $1.84. Revenue for the quarter came in at $592.1 million versus the consensus estimate of $586.97 million.
Bio-Rad is updating its financial outlook for the full-year 2026. The Company currently expects non-GAAP,... More
